The primary and secondary antibodies used in this study are shown as follows and in table S3: anti-Myc (1:2000 dilution), anti-Flag (1:2000 dilution), anti-PGP9.5/UCHL1 (1:800 dilution), anti-GFP (1:5000 dilution), anti-sarcomeric α-actinin (1:200 dilution), anti-EGFR (1:1000 dilution), anti–phospho-EGFR (1:1000 dilution), anti-ubiquitin (1:1000 dilution), anti-AT1/AT1R (1:800 dilution), anti–insulin-like growth factor 1R (IGF1R) (1:1000 dilution), anti-gp130 (1:800 dilution), anti-ErBb2 (1:1000 dilution), anti-ErBb3 (1: 1000 dilution), anti-ErBb4 (1:600 dilution), anti-mouse lgG (1:3000 dilution), anti-rabbit lgG (1:3000 dilution), anti-AKT (1:1000 dilution), anti–phospho-AKT (1:1000 dilution), anti-ERK1/2 (1:2000 dilution), anti–phospho-ERK1/2 (1:1000 dilution), and GAPDH (1:3000 dilution).

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.